Business Description
Vor Biopharma is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing treatments for acute myeloid leukemia and other blood cancers. Its core approach involves engineering stem cells to make them resistant to cancer-targeting therapies, allowing more aggressive treatment with less harm to healthy cells. The company's leading program is currently in Phase 1/2 clinical trials, with several additional therapies in earlier stages of development. Vor Biopharma was founded in 2015 and holds licensing agreements with Columbia University, the National Institutes of Health, and Editas Medicine.
